Fortis Life Sciences acquires Abcore

By The Science Advisory Board staff writers

March 4, 2022 -- Fortis Life Sciences has acquired Abcore, extending Fortis’ capabilities into the antibody discovery market serving biopharma customers developing antibody and nanobody-based therapeutics.

Abcore provides antibody and nanobody products and services. Abcore has built an entire platform for nanobody and single domain (VHH) antibody discovery, based on proprietary phage display libraries.

Fortis Life Sciences is a strategic platform company providing capital, expertise, and operational resources to enable the growth and success of founder-led life sciences tools companies.

Financial details of the acquisition were not disclosed.


Copyright © 2022 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.